• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes

    2/10/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TWST alert in real time by email

    Twist TrueAmp Library Preparation Kit with in-house developed enzymes including new Twist TrueAmp Polymerase

    Twist PCR-Free WGS Library Preparation Kit designed to meet the needs of the growing whole genome sequencing market

    New kits compatible with additional Twist NGS Applications tools for complete target enrichment and WGS library prep workflows

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research.

    The Twist TrueAmp Library Prep Kit brings a new level of exceptional performance to Twist's library preparation portfolio, with advantages enabled by Twist in-house developed enzymes, including a previously developed ligase as well as a newly developed polymerase. Engineered for next generation sequencing applications, the specialized TrueAmp polymerase maximizes coverage across typically hard-to-sequence regions of the genome, while maintaining high accuracy during DNA copying. The kit ensures high yields even from low-input or degraded starting samples, which minimizes amplification-introduced errors and results in more usable high-quality data. To streamline large-scale workflows, the Twist TrueAmp Library Prep Kit has been validated with the Twist HT-UDI adapter system, allowing for up to 3,072 unique indexes as well as Twist UMI adapters, ensuring precise strand identification and efficient multiplexing.

    To serve customers across sequencing applications, Twist developed a complementary PCR-free version of the kit for researchers conducting whole genome sequencing (WGS). Leveraging Twist's engineered ligase, the Twist PCR-Free WGS Library Preparation Kit efficiently converts starting DNA without bias commonly seen in whole genome sequencing. Precisely optimized enzymatic fragmentation conditions deliver consistent outputs that maximize sequencing efficiency and improve data quality. Validated with Twist's full length UDI adapters, the PCR-Free WGS Kit supports unique barcoding for up to 1,536 samples, enabling researchers to easily scale their workflows. The PCR-Free WGS Kit allows Twist to further serve customers using whole genome sequencing for approaches where low pass sequencing is sufficient, such as rare disease, while in parallel providing researchers working in areas that require deep sequencing, such as cancer, with panels and other tools to support their research.

    "Twist's engineered enzymes are powering our next generation of library preparation kits with the goal of more accurate variant detection, more robust performance from difficult samples, and easy-to-use workflows," said Emily M. Leproust, CEO and co-founder of Twist Bioscience. "We are developing new solutions with a clear focus on the unique sequencing methodologies required for various clinical and research applications, whether broad whole genome sequencing or more targeted approaches. With our TrueAmp polymerase, we are overcoming common challenges our customers face with difficult sample types and costly run failures. We will continue to leverage our high-performing engineered enzymes and develop new enzymes to deliver even higher quality performance for our customers, raising the bar not just for ourselves but for the industry."

    "At Gene by Gene, we pride ourselves in providing affordable high-quality genetic testing services," said Josh Wittner President, North America, Gene by Gene. "With the Twist TrueAmp Library Prep Kit, we're able to scale our business to deliver on our promise to our customers. We can now make the most of each sample and every read, even across multiple sequencing platforms."

    "With the Twist WGS kit, we're seeing significantly lower dropout rates and PCR duplication rates compared to another library prep workflow," said Junior Associate Professor, Dr. Daisuke Motooka, Osaka University. "These improvements are critical in detecting rare variants and reducing the chances of false reads."

    Twist TrueAmp Library Preparation Kit

    The Twist TrueAmp Library Preparation Kit is designed to deliver consistent, high-quality libraries for NGS target enrichment workflows, particularly with low-input or challenging samples, such as FFPE. Powered by Twist's in-house developed polymerase and ligase, the workflow provides high-fidelity amplification for confident variant detection, minimizing amplification-induced errors and bias, and supporting reliable detection of low-frequency variants. The kit features tunable enzymatic fragmentation, producing larger, uniform library fragments across a broad range of inputs, while maintaining uniform sequence coverage and low bias even in difficult genomic regions. With high conversion efficiency and robust performance across variable sample types, researchers can recover more usable sequencing data from precious or degraded samples, achieving high library yields that reduce the need for reruns and increase confidence in downstream analysis. The TrueAmp Library Prep Kit can be used with Twist target enrichment and adapters for a complete library prep workflow. The TrueAmp polymerase hot start functionality is developed in collaboration with Aptamer Group plc.

    Twist PCR-Free Whole Genome Sequencing (WGS) Library Preparation Kit

    The Twist PCR-Free Whole Genome Sequencing (WGS) Library Preparation Kit delivers high-yield sequencing from low-input or degraded samples without amplification, preserving native DNA representation and avoiding amplification bias, AT dropouts and artificial mutations. Leveraging an in-house developed ligase, the workflow enables high conversion and uniformity, while tunable fragmentation and full-length adapters produce consistent, large library fragments that improve read utilization and maximize sequencing reads. Suitable for a variety of sample types, the PCR-Free WGS Kit enables researchers to generate reliable sequencing results with less starting material. The WGS Kit can be used with Twist's full length UDI adapters for a complete WGS library prep workflow.

    About Twist Bioscience Corporation

    At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

    Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com.

    Follow us on LinkedIn | X | YouTube | Instagram | Bluesky

    Twist Bioscience Legal Notice Regarding Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected performance and benefits of new library preparation kits and the company's plans for continued enzyme development and innovation. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2025 filed with the Securities and Exchange Commission (SEC) on November 17, 2025 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260210202871/en/

    For Investors:

    Angela Bitting

    SVP, Corporate Affairs

    925-202-6211

    abitting@twistbioscience.com

    For Media:

    Amanda Houlihan

    Communications Manager

    774-265-5334

    ahoulihan@twistbioscience.com

    Get the next $TWST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TWST

    DatePrice TargetRatingAnalyst
    5/5/2026$70.00Market Perform → Outperform
    Leerink Partners
    11/4/2025$41.00Overweight
    Stephens
    12/13/2024$60.00Outperform
    Wolfe Research
    6/4/2024$53.00Buy
    Guggenheim
    1/17/2024$25.00 → $45.00Neutral → Buy
    Goldman
    9/27/2023$27.00Buy
    Berenberg
    1/5/2023$33.00Sector Outperform
    Scotiabank
    1/3/2023$28.00 → $36.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $TWST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist Bioscience will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events. About Twist Bioscience Corporation At Twist Bioscience,

    5/27/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units ("RSUs") and up to 13,348 performance stock units ("PSUs"), will be granted to 53 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist's Amended and Restated Inducement Equity Incentive Plan and related form of restricted stock unit award agreement in accordance with Nasdaq Listing Rule 5635(c)(4). The indu

    5/5/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

    Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products Complex synthesis capabilities to support further advancement of AI-enabled drug discovery and nucleic acid therapeutics Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes. "As research in nucleic acid therapeutics and AI-guided protein design and therapeutics discovery accelerate, scientists need a reliable partner to consistently deliver genes rapidly at scale and with more complex sequences,"

    5/4/26 7:20:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    SEC Filings

    View All

    SEC Form 144 filed by Twist Bioscience Corporation

    144 - Twist Bioscience Corp (0001581280) (Subject)

    5/12/26 9:48:44 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Twist Bioscience Corporation

    10-Q - Twist Bioscience Corp (0001581280) (Filer)

    5/4/26 4:28:48 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Twist Bioscience Corporation

    144 - Twist Bioscience Corp (0001581280) (Subject)

    5/4/26 3:20:53 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Twist Bioscience upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Twist Bioscience from Market Perform to Outperform and set a new price target of $70.00

    5/5/26 7:00:58 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stephens initiated coverage on Twist Bioscience with a new price target

    Stephens initiated coverage of Twist Bioscience with a rating of Overweight and set a new price target of $41.00

    11/4/25 7:44:48 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Twist Bioscience with a new price target

    Wolfe Research initiated coverage of Twist Bioscience with a rating of Outperform and set a new price target of $60.00

    12/13/24 8:32:53 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

    For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

    3/26/21 3:51:09 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Laponis Adam sold $280,000 worth of shares (4,000 units at $70.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 112,675 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    6/2/26 4:05:30 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Cho Dennis sold $990,799 worth of shares (14,205 units at $69.75) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 120,094 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    6/2/26 4:05:31 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Starovasnik Melissa A. sold $170,000 worth of shares (2,500 units at $68.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 22,222 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    6/1/26 4:05:05 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Leadership Updates

    Live Leadership Updates

    View All

    Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. "Trynka is an accomplished global leader with a proven track record of driving profitable growth and innovation of custom products at scale," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bios

    8/6/25 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire) "Mike's extensive background in building and configuring scalable enterprise softwar

    10/15/24 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240105333128/en/Adam Laponis, chief financial officer of Twist Bioscience (Photo: Business Wire) "Adam's deep financial acumen and strategic planning expertise across diverse businesses make him

    1/5/24 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Financials

    Live finance-specific insights

    View All

    Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal second quarter 2026 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company's b

    5/4/26 7:15:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026

    Company to host conference call at 8:00 AM ET Investor Day Scheduled for May 21, 2026 Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 second quarter ended March 31, 2026, before the opening of the market on May 4, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor Relations secti

    4/21/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

    B-Body® platform complements Twist's antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. ("Invenra"), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra's B-Bo

    2/17/26 7:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

    SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 2:38:08 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Twist Bioscience Corporation

    SC 13G - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 9:39:34 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

    SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    11/5/24 6:07:26 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care